Clinical Pharmacology Update: Duzallo
February 24, 2018
The FDA has approved Duzallo (lesinurad and allopurinol; Ironwood Pharmaceuticals, Inc) for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone.